Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Risvodetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SynuSight, ABLi Partner to Add Alpha-Syn PET to PD Trials
    SynuSight, ABLi Partner to Add Alpha-Syn PET to PD Trials

    05 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synusight-biotech-abli-therapeutics-and-xingimaging-announce-strategic-collaboration-to-implement-alpha-synuclein-pet-imaging-into-clinical-trials-evaluating-risvodetinib-as-a-disease-modifying-therapy-for-parkinsons-disease-302652273.html

    PR NEWSWIRE
    05 Jan 2026
    Share Share
    CND Life Sciences Uses Syn-One In Ph2 Trial Parkinson’s Endpoint
    CND Life Sciences Uses Syn-One In Ph2 Trial Parkinson’s Endpoint

    11 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cnd-life-sciences-syn-one-biomarker-services-used-for-novel-parkinsons-disease-endpoint-in-phase-2-drug-trial-302610938.html

    PR NEWSWIRE
    11 Nov 2025
    Share Share
    Ablin Therapeutics Releases Phase 2 Trial Results
    Ablin Therapeutics Releases Phase 2 Trial Results

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164057/0/en/ABLi-Therapeutics-Reports-Final-Results-from-the-Phase-2-201-Trial-Evaluating-Risvodetinib-for-the-Treatment-of-Parkinson-s-Disease.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    ABLi Therapeutics to Speak at 2025 Parkinson’s Disease Congress
    ABLi Therapeutics to Speak at 2025 Parkinson’s Disease Congress

    15 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/15/3149944/0/en/ABLi-Therapeutics-to-Present-Clinical-Breakthrough-Lecture-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html

    GLOBENEWSWIRE
    15 Sep 2025
    Share Share
    Inhibikase Therapeutics Reports Q2 Financial Results And Recent Activity
    Inhibikase Therapeutics Reports Q2 Financial Results And Recent Activity

    14 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/14/2930514/0/en/Inhibikase-Therapeutics-Reports-Second-Quarter-Financial-Results-and-Highlights-Recent-Period-Activity.html

    GLOBENEWSWIRE
    14 Aug 2024
    Share Share
    Inhibikase Completes Enrollment Of Phase 2 Trial For Risvodetinib In Parkinson’s
    Inhibikase Completes Enrollment Of Phase 2 Trial For Risvodetinib In Parkinson’s

    17 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/17/2899626/0/en/Inhibikase-Therapeutics-Completes-Enrollment-of-the-Phase-2-201-Trial-Evaluating-Risvodetinib-in-Untreated-Parkinson-s-Disease.html

    GLOBENEWSWIRE
    17 Jun 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.